Every earnings call for COHANCE — management tone, guidance, KPIs and promise tracking, quarter by quarter.
COHANCE · 7 transcripts · Healthcare · latest Q4 FY26Cohance Lifesciences Limited has 7 earnings calls on record here, a Healthcare company, most recently Q4 FY26. Each quarter is scored on revenue, margins, guidance delivery and the questions management left unanswered — so the gap between what was promised and what was delivered is easy to read.
Revenue ₹2,268 cr (−13% YoY); Adjusted EBITDA ₹477 cr; EBITDA Margin 21.0%. FY26 Revenue stood at INR 2,268 crores, a decline of 13% YoY.
Read full transcript & analysisRevenue (9M FY26) ₹1,650 cr (−7% YoY); Adjusted EBITDA (9M FY26) ₹348 cr (−43% YoY); Adjusted EBITDA Margin (9M FY26) 21.0%. Nine-month FY26 revenue declined by 6.7% to INR1,650 crore.
Read full transcript & analysisManagement announced a major leadership transition with Managing Director Dr. Prasada Raju stepping down; he will remain for a transition period until the end of the fiscal year.
Read full transcript & analysisRevenue Growth 13% (+13% YoY); Free Cash Flow ₹230 cr; Cash Balance ₹440 cr. Reported revenue growth of 13% YoY, driven by Specialty Chemicals and API segments.
Read full transcript & analysisRevenue 335 million USD (+9% YoY); EBITDA Margin 34%. Full year FY25 revenue reached $335 million with a 9% YoY growth rate.
Read full transcript & analysisAdjusted EBITDA Margin 38.7%. Pro forma combined revenue grew 40% YoY in Q3 FY25, driven by robust demand across business units.
Read full transcript & analysisNJ Bio Revenue (CY24) 32 million USD (+70% YoY); Total Acquisition Investment 64.4 million USD; Suven Cash Reserve 6.5 billion INR. Acquisition of 56% controlling stake in NJ Bio, Inc. for a total investment of $64.4 million.
Read full transcript & analysis